Anticonvulsants Drugs Market is expected to grow at a CAGR of 5.92% during the forecast period. Global Anticonvulsants Drugs Market is expected to reach US$ 22.80 Bn. by 2029.Anticonvulsants Drugs Market overview:
Anticonvulsants are a diverse group of pharmacological agents used in the treatment of epileptic seizures. They are also increasingly used in the treatment of bipolar disorder and Borderline personality disorder. Anticonvulsants prevent the spread of seizures in the brain. Anticonvulsant drugs are primarily developed for the treatment of epilepsy, a neurological condition that affects around 50 million people worldwide. The report covers the detailed analysis of the global Anticonvulsants Drugs industry with the classifications of the market on the therapeutic class and disease indication. Analysis of past market dynamics from 2017 to 2021 is given in the report, which will help readers to benchmark the past trends with current market scenarios with the key player's contribution in it.To know about the Research Methodology :- Request Free Sample Report The report has profiled fifteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. Manufacturing environment in each region is different and focus is given on the regional impact on the cost of treatment, availability of advanced technology, end-users are analysed and report has come up with recommendations for future hot spot in APAC region.
Anticonvulsants Drugs Market Dynamics:
The rising prevalence of epilepsy and increasing awareness about anticonvulsants drugs are the key drivers of the market. Anticonvulsants are also used for pain management in migraine and fibromyalgia, which helps in fostering the growth of the market. Of the major anticonvulsant drugs, Lyrica in 2012 registered the dominant share of $xx Mn, of which 74% constituted from its pain management indication. Availability of alternative options for pain management, which includes the use of medical devices such as analgesic pumps and minimally invasive procedures such as denervation or rhizotomy, act as major restraints of the market. Besides this, high costs and unavailability of convenient dosage forms of both generic and branded anticonvulsants are restraining the growth of novel therapies in the anticonvulsants market.Anticonvulsants Drugs Market Regional Insights:
North America is expected to account largest market share of xx% during the forecast period. North America is expected to hold the dominant position in the anticonvulsants market during the forecast period, owing to the increasing prevalence of epilepsy and launching of new generic drugs. For instance, according to the Centers for Disease Control and Prevention, in 2021, around 3.4 million people had active epilepsy in the U.S., which included 3 million adults and 470,000 children. Asia Pacific is forecasted to be the fastest growing region during the period 2021-2029: Increasing medical tourism in countries such as India, China, and Japan and increasing launches of antiepileptic drugs by key players are the key factors for the growth of the market in APAC. For instance, in February 2021, Eisai Co., Ltd. launched antiepileptic drug (AED), Fycompa, indicated for adjunctive treatment of partial-onset seizures in epilepsy patients aged 12 years and above.Anticonvulsants Drugs Market segmentation:
Therapeutic class segment analysis: • From the therapeutic class segment,Barbiturates are the most widely used drug class for the treatment of epilepsy. They are also useful for inducing anesthesia. Phenobarbitalhas extensive use as an antiepileptic drug in the neonatal and pediatricpopulation. It is the most cost-effective drug treatment for epilepsy in adultsin low resource countries. The worldwidemarket for Barbiturate Drugs is expected to grow at a CAGR of xx% over the nextfive years. It is expected to reach $xx Mn in 2023, from $xx Mn in 2021, accordingto a new study. North America is expected to accountfor the largest share of the global market from 2021 to 2029, due to the highestpercentage of insomnia affected patients. The objective of the report is to present a comprehensive analysis of the Global Anticonvulsants Drugs Market to the stakeholders in the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Anticonvulsants Drugs Market dynamics, structure by analyzing the market segments and project the Global Anticonvulsants Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Anticonvulsants Drugs Market make the report investor’s guide.Anticonvulsants Drugs Market Scope: Inquire before buying
Global Anticonvulsants Drugs Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US $ 14.39 Bn. Forecast Period 2022 to 2029 CAGR: 5.92% Market Size in 2029: US $ 22.80 Bn. Segments Covered: by Therapeutic Class • Barbiturates • Benzodiazepines • Hydantoins • Succinimides by Disease Indication • Epilepsy • Fibromyalgia • Migraine • Neuropathic pain • Bipolar disorder • Borderline personality disorder by Formulation • Enteral Tablets Capsules • Parenteral Liquid Lyophilized • Topical Rectal gels Creams Others by Distribution Channels • Hospital Pharmacies • Online Pharmacies • Retail Pharmacies • Drug stores Anticonvulsants drugs market Key players are:
• Abbott Laboratories • Teva Pharmaceuticals • Johnson & Johnson • Novartis • Pfizer • Valeant pharmaceuticals • Sanofi • UCB • Shire • AstraZeneca • GlaxoSmithKline • Sunovion Pharmaceuticals • GW Pharmaceuticals • H. Lundbeck • Cephalon Inc. • Sumitomo Dainippon Pharma Frequently Asked Questions: 1. Which region has the largest share in Global Anticonvulsants drugs Market? Ans: North America region held the highest share in 2021. 2. What is the growth rate of Global Anticonvulsants drugs Market? Ans: The Global Anticonvulsants drugs Market is growing at a CAGR of 5.92% during forecasting period 2022-2029. 3. What is scope of the Global Anticonvulsants drugs market report? Ans: Global Anticonvulsants drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Anticonvulsants drugs market? Ans: The important key players in the Global Anticonvulsants drugs Market are – Abbott Laboratories, Teva Pharmaceuticals, Johnson & Johnson, Novartis, Pfizer, Valeant pharmaceuticals, Sanofi, UCB, Shire, AstraZeneca, GlaxoSmithKline, Sunovion Pharmaceuticals, GW Pharmaceuticals, H. Lundbeck, Cephalon Inc., and Sumitomo Dainippon Pharma 5. What is the study period of this market? Ans: The Global Anticonvulsants drugs Market is studied from 2021 to 2029.
Global Anticonvulsants Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: ANTICONVULSANTS DRUGS Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global ANTICONVULSANTS DRUGS Market Analysis and Forecast 6.1. ANTICONVULSANTS DRUGS Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global ANTICONVULSANTS DRUGS Market Analysis and Forecast, By Therapeutic Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. ANTICONVULSANTS DRUGS Market Value Share Analysis, By Therapeutic Class 7.4. ANTICONVULSANTS DRUGS Market Size (US$ Mn) Forecast, By Therapeutic Class 7.5. ANTICONVULSANTS DRUGS Market Analysis, By Therapeutic Class 7.6. ANTICONVULSANTS DRUGS Market Attractiveness Analysis, By Therapeutic Class 8. Global ANTICONVULSANTS DRUGS Market Analysis and Forecast, By Disease Indication 8.1. Introduction and Definition 8.2. Key Findings 8.3. ANTICONVULSANTS DRUGS Market Value Share Analysis, By Disease Indication 8.4. ANTICONVULSANTS DRUGS Market Size (US$ Mn) Forecast, By Disease Indication 8.5. ANTICONVULSANTS DRUGS Market Analysis, By Disease Indication 8.6. ANTICONVULSANTS DRUGS Market Attractiveness Analysis, By Disease Indication 9. Global ANTICONVULSANTS DRUGS Market Analysis and Forecast By Formulation 9.1. Introduction and Definition 9.2. Key Findings 9.3. ANTICONVULSANTS DRUGS Market Value Share Analysis, By Formulation 9.4. ANTICONVULSANTS DRUGS Market Size (US$ Mn) Forecast, By Formulation 9.5. ANTICONVULSANTS DRUGS Market Analysis, By Formulation 9.6. ANTICONVULSANTS DRUGS Market Attractiveness Analysis, By Formulation 10. Global ANTICONVULSANTS DRUGS Market Analysis and Forecast By Distribution Channels 10.1. Introduction and Definition 10.2. Key Findings 10.3. ANTICONVULSANTS DRUGS Market Value Share Analysis, By Distribution Channels 10.4. ANTICONVULSANTS DRUGS Market Size (US$ Mn) Forecast, By Distribution Channels 10.5. ANTICONVULSANTS DRUGS Market Analysis, By Distribution Channels 10.6. ANTICONVULSANTS DRUGS Market Attractiveness Analysis, By Distribution Channels 11. Global ANTICONVULSANTS DRUGS Market Analysis, By Region 11.1. ANTICONVULSANTS DRUGS Market Value Share Analysis, By Region 11.2. ANTICONVULSANTS DRUGS Market Size (US$ Mn) Forecast, By Region 11.3. ANTICONVULSANTS DRUGS Market Attractiveness Analysis, By Region 12. North America ANTICONVULSANTS DRUGS Market Analysis 12.1. Key Findings 12.2. North America ANTICONVULSANTS DRUGS Market Overview 12.3. North America ANTICONVULSANTS DRUGS Market Value Share Analysis, By Therapeutic Class 12.4. North America ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 12.4.1. Barbiturates 12.4.2. Benzodiazepines 12.4.3. Hydantoins 12.4.4. Succinimides 12.5. North America ANTICONVULSANTS DRUGS Market Value Share Analysis, By Disease Indication 12.6. North America ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 12.6.1. Epilepsy 12.6.2. Fibromyalgia 12.6.3. Migraine 12.6.4. Neuropathic pain 12.6.5. Bipolar disorder 12.6.6. Borderline personality disorder 12.7. North America ANTICONVULSANTS DRUGS Market Value Share Analysis, By Formulation 12.8. North America ANTICONVULSANTS DRUGS Market Forecast, By Formulation 12.8.1. Enteral 12.8.2. Parenteral 12.8.3. Topical 12.9. North America ANTICONVULSANTS DRUGS Market Value Share Analysis, By Distribution Channels 12.10. North America ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 12.10.1. Hospital Pharmacies 12.10.2. Online Pharmacies 12.10.3. Retail Pharmacies 12.10.4. Drug stores 12.11. North America ANTICONVULSANTS DRUGS Market Value Share Analysis, By Country 12.12. North America ANTICONVULSANTS DRUGS Market Forecast, By Country 12.12.1. U.S. 12.12.2. Canada 12.12.3. Mexico 12.13. North America ANTICONVULSANTS DRUGS Market Analysis, By Country 12.14. U.S. ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 12.14.1. Barbiturates 12.14.2. Benzodiazepines 12.14.3. Hydantoins 12.14.4. Succinimides 12.15. U.S. ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 12.15.1. Epilepsy 12.15.2. Fibromyalgia 12.15.3. Migraine 12.15.4. Neuropathic pain 12.15.5. Bipolar disorder 12.15.6. Borderline personality disorder 12.16. U.S. ANTICONVULSANTS DRUGS Market Forecast, By Formulation 12.16.1. Enteral 12.16.2. Parenteral 12.16.3. Topical 12.17. U.S. ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 12.17.1. Hospital Pharmacies 12.17.2. Online Pharmacies 12.17.3. Retail Pharmacies 12.17.4. Drug stores 12.18. Canada ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 12.18.1. Barbiturates 12.18.2. Benzodiazepines 12.18.3. Hydantoins 12.18.4. Succinimides 12.19. Canada ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 12.19.1. Epilepsy 12.19.2. Fibromyalgia 12.19.3. Migraine 12.19.4. Neuropathic pain 12.19.5. Bipolar disorder 12.19.6. Borderline personality disorder 12.20. Canada ANTICONVULSANTS DRUGS Market Forecast, By Formulation 12.20.1. Enteral 12.20.2. Parenteral 12.20.3. Topical 12.21. Canada ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 12.21.1. Hospital Pharmacies 12.21.2. Online Pharmacies 12.21.3. Retail Pharmacies 12.21.4. Drug stores 12.22. Mexico ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 12.22.1. Barbiturates 12.22.2. Benzodiazepines 12.22.3. Hydantoins 12.22.4. Succinimides 12.23. Mexico ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 12.23.1. Epilepsy 12.23.2. Fibromyalgia 12.23.3. Migraine 12.23.4. Neuropathic pain 12.23.5. Bipolar disorder 12.23.6. Borderline personality disorder 12.24. Mexico ANTICONVULSANTS DRUGS Market Forecast, By Formulation 12.24.1. Enteral 12.24.2. Parenteral 12.24.3. Topical 12.25. Mexico ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 12.25.1. Hospital Pharmacies 12.25.2. Online Pharmacies 12.25.3. Retail Pharmacies 12.25.4. Drug stores 12.26. North America ANTICONVULSANTS DRUGS Market Attractiveness Analysis 12.26.1. By Therapeutic Class 12.26.2. By Disease Indication 12.26.3. By Formulation 12.26.4. By Distribution Channels 12.27. PEST Analysis 12.28. Key Trends 12.29. Key Developments 13. Europe ANTICONVULSANTS DRUGS Market Analysis 13.1. Key Findings 13.2. Europe ANTICONVULSANTS DRUGS Market Overview 13.3. Europe ANTICONVULSANTS DRUGS Market Value Share Analysis, By Therapeutic Class 13.4. Europe ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 13.4.1. Barbiturates 13.4.2. Benzodiazepines 13.4.3. Hydantoins 13.4.4. Succinimides 13.5. Europe ANTICONVULSANTS DRUGS Market Value Share Analysis, By Disease Indication 13.6. Europe ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 13.6.1. Epilepsy 13.6.2. Fibromyalgia 13.6.3. Migraine 13.6.4. Neuropathic pain 13.6.5. Bipolar disorder 13.6.6. Borderline personality disorder 13.7. Europe ANTICONVULSANTS DRUGS Market Value Share Analysis, By Formulation 13.8. Europe ANTICONVULSANTS DRUGS Market Forecast, By Formulation 13.8.1. Enteral 13.8.2. Parenteral 13.8.3. Topical 13.9. Europe ANTICONVULSANTS DRUGS Market Value Share Analysis, By Distribution Channels 13.10. Europe ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 13.10.1. Hospital Pharmacies 13.10.2. Online Pharmacies 13.10.3. Retail Pharmacies 13.10.4. Drug stores 13.11. Europe ANTICONVULSANTS DRUGS Market Value Share Analysis, By Country 13.12. Europe ANTICONVULSANTS DRUGS Market Forecast, By Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Sweden 13.12.7. CIS countries 13.12.8. Rest of Europe 13.13. Germany ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 13.13.1. Barbiturates 13.13.2. Benzodiazepines 13.13.3. Hydantoins 13.13.4. Succinimides 13.14. Germany ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 13.14.1. Epilepsy 13.14.2. Fibromyalgia 13.14.3. Migraine 13.14.4. Neuropathic pain 13.14.5. Bipolar disorder 13.14.6. Borderline personality disorder 13.15. Germany ANTICONVULSANTS DRUGS Market Forecast, By Formulation 13.15.1. Enteral 13.15.2. Parenteral 13.15.3. Topical 13.16. Germany ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 13.16.1. Hospital Pharmacies 13.16.2. Online Pharmacies 13.16.3. Retail Pharmacies 13.16.4. Drug stores 13.17. U.K. ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 13.17.1. Barbiturates 13.17.2. Benzodiazepines 13.17.3. Hydantoins 13.17.4. Succinimides 13.18. U.K. ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 13.18.1. Epilepsy 13.18.2. Fibromyalgia 13.18.3. Migraine 13.18.4. Neuropathic pain 13.18.5. Bipolar disorder 13.18.6. Borderline personality disorder 13.19. U.K. ANTICONVULSANTS DRUGS Market Forecast, By Formulation 13.19.1. Enteral 13.19.2. Parenteral 13.19.3. Topical 13.20. U.K. ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 13.20.1. Hospital Pharmacies 13.20.2. Online Pharmacies 13.20.3. Retail Pharmacies 13.20.4. Drug stores 13.21. France ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 13.21.1. Barbiturates 13.21.2. Benzodiazepines 13.21.3. Hydantoins 13.21.4. Succinimides 13.22. France ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 13.22.1. Epilepsy 13.22.2. Fibromyalgia 13.22.3. Migraine 13.22.4. Neuropathic pain 13.22.5. Bipolar disorder 13.22.6. Borderline personality disorder 13.23. France ANTICONVULSANTS DRUGS Market Forecast, By Formulation 13.23.1. Enteral 13.23.2. Parenteral 13.23.3. Topical 13.24. France ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 13.24.1. Hospital Pharmacies 13.24.2. Online Pharmacies 13.24.3. Retail Pharmacies 13.24.4. Drug stores 13.25. Italy ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 13.25.1. Barbiturates 13.25.2. Benzodiazepines 13.25.3. Hydantoins 13.25.4. Succinimides 13.26. Italy ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 13.26.1. Epilepsy 13.26.2. Fibromyalgia 13.26.3. Migraine 13.26.4. Neuropathic pain 13.26.5. Bipolar disorder 13.26.6. Borderline personality disorder 13.27. Italy ANTICONVULSANTS DRUGS Market Forecast, By Formulation 13.27.1. Enteral 13.27.2. Parenteral 13.27.3. Topical 13.28. Italy ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 13.28.1. Hospital Pharmacies 13.28.2. Online Pharmacies 13.28.3. Retail Pharmacies 13.28.4. Drug stores 13.29. Spain ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 13.29.1. Barbiturates 13.29.2. Benzodiazepines 13.29.3. Hydantoins 13.29.4. Succinimides 13.30. Spain ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 13.30.1. Epilepsy 13.30.2. Fibromyalgia 13.30.3. Migraine 13.30.4. Neuropathic pain 13.30.5. Bipolar disorder 13.30.6. Borderline personality disorder 13.31. Spain ANTICONVULSANTS DRUGS Market Forecast, By Formulation 13.31.1. Enteral 13.31.2. Parenteral 13.31.3. Topical 13.32. Spain ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 13.32.1. Hospital Pharmacies 13.32.2. Online Pharmacies 13.32.3. Retail Pharmacies 13.32.4. Drug stores 13.33. Sweden ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 13.33.1. Barbiturates 13.33.2. Benzodiazepines 13.33.3. Hydantoins 13.33.4. Succinimides 13.34. Sweden ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 13.34.1. Epilepsy 13.34.2. Fibromyalgia 13.34.3. Migraine 13.34.4. Neuropathic pain 13.34.5. Bipolar disorder 13.34.6. Borderline personality disorder 13.35. Sweden ANTICONVULSANTS DRUGS Market Forecast, By Formulation 13.35.1. Enteral 13.35.2. Parenteral 13.35.3. Topical 13.36. Sweden ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 13.36.1. Hospital Pharmacies 13.36.2. Online Pharmacies 13.36.3. Retail Pharmacies 13.36.4. Drug stores 13.37. CIS countries ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 13.37.1. Barbiturates 13.37.2. Benzodiazepines 13.37.3. Hydantoins 13.37.4. Succinimides 13.38. CIS countries ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 13.38.1. Epilepsy 13.38.2. Fibromyalgia 13.38.3. Migraine 13.38.4. Neuropathic pain 13.38.5. Bipolar disorder 13.38.6. Borderline personality disorder 13.39. CIS countries ANTICONVULSANTS DRUGS Market Forecast, By Formulation 13.39.1. Enteral 13.39.2. Parenteral 13.39.3. Topical 13.40. CIS countries ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 13.40.1. Hospital Pharmacies 13.40.2. Online Pharmacies 13.40.3. Retail Pharmacies 13.40.4. Drug stores 13.41. Rest of Europe ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 13.41.1. Barbiturates 13.41.2. Benzodiazepines 13.41.3. Hydantoins 13.41.4. Succinimides 13.42. Rest of Europe ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 13.42.1. Epilepsy 13.42.2. Fibromyalgia 13.42.3. Migraine 13.42.4. Neuropathic pain 13.42.5. Bipolar disorder 13.42.6. Borderline personality disorder 13.43. Rest of Europe ANTICONVULSANTS DRUGS Market Forecast, By Formulation 13.43.1. Enteral 13.43.2. Parenteral 13.43.3. Topical 13.44. Rest of Europe ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 13.44.1. Hospital Pharmacies 13.44.2. Online Pharmacies 13.44.3. Retail Pharmacies 13.44.4. Drug stores 13.45. Europe ANTICONVULSANTS DRUGS Market Attractiveness Analysis 13.45.1. By Disease Indication 13.45.2. By Therapeutic Class 13.45.3. By Formulation 13.45.4. By Distribution Channels 13.46. PEST Analysis 13.47. Key Trends 13.48. Key Developments 14. Asia Pacific ANTICONVULSANTS DRUGS Market Analysis 14.1. Key Findings 14.2. Asia Pacific ANTICONVULSANTS DRUGS Market Overview 14.3. Asia Pacific ANTICONVULSANTS DRUGS Market Value Share Analysis, By Therapeutic Class 14.4. Asia Pacific ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 14.4.1. Barbiturates 14.4.2. Benzodiazepines 14.4.3. Hydantoins 14.4.4. Succinimides 14.5. Asia Pacific ANTICONVULSANTS DRUGS Market Value Share Analysis, By Disease Indication 14.6. Asia Pacific ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 14.6.1. Epilepsy 14.6.2. Fibromyalgia 14.6.3. Migraine 14.6.4. Neuropathic pain 14.6.5. Bipolar disorder 14.6.6. Borderline personality disorder 14.7. Asia Pacific ANTICONVULSANTS DRUGS Market Value Share Analysis, By Formulation 14.8. Asia Pacific ANTICONVULSANTS DRUGS Market Forecast, By Formulation 14.8.1. Enteral 14.8.2. Parenteral 14.8.3. Topical 14.9. Asia Pacific ANTICONVULSANTS DRUGS Market Value Share Analysis, By Distribution Channels 14.10. Asia Pacific ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 14.10.1. Hospital Pharmacies 14.10.2. Online Pharmacies 14.10.3. Retail Pharmacies 14.10.4. Drug stores 14.11. Asia Pacific ANTICONVULSANTS DRUGS Market Value Share Analysis, By Country 14.12. Asia Pacific ANTICONVULSANTS DRUGS Market Forecast, By Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. South Korea 14.12.5. Australia 14.12.6. ASEAN 14.12.7. Rest of Asia Pacific 14.13. Asia Pacific ANTICONVULSANTS DRUGS Market Analysis, By Country 14.14. China ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 14.14.1. Barbiturates 14.14.2. Benzodiazepines 14.14.3. Hydantoins 14.14.4. Succinimides 14.15. China ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 14.15.1. Epilepsy 14.15.2. Fibromyalgia 14.15.3. Migraine 14.15.4. Neuropathic pain 14.15.5. Bipolar disorder 14.15.6. Borderline personality disorder 14.16. China ANTICONVULSANTS DRUGS Market Forecast, By Formulation 14.16.1. Enteral 14.16.2. Parenteral 14.16.3. Topical 14.17. China ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 14.17.1. Hospital Pharmacies 14.17.2. Online Pharmacies 14.17.3. Retail Pharmacies 14.17.4. Drug stores 14.18. India ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 14.18.1. Barbiturates 14.18.2. Benzodiazepines 14.18.3. Hydantoins 14.18.4. Succinimides 14.19. India ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 14.19.1. Epilepsy 14.19.2. Fibromyalgia 14.19.3. Migraine 14.19.4. Neuropathic pain 14.19.5. Bipolar disorder 14.19.6. Borderline personality disorder 14.20. India ANTICONVULSANTS DRUGS Market Forecast, By Formulation 14.20.1. Enteral 14.20.2. Parenteral 14.20.3. Topical 14.21. India ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 14.21.1. Hospital Pharmacies 14.21.2. Online Pharmacies 14.21.3. Retail Pharmacies 14.21.4. Drug stores 14.22. Japan ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 14.22.1. Barbiturates 14.22.2. Benzodiazepines 14.22.3. Hydantoins 14.22.4. Succinimides 14.23. Japan ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 14.23.1. Epilepsy 14.23.2. Fibromyalgia 14.23.3. Migraine 14.23.4. Neuropathic pain 14.23.5. Bipolar disorder 14.23.6. Borderline personality disorder 14.24. Japan ANTICONVULSANTS DRUGS Market Forecast, By Formulation 14.24.1. Enteral 14.24.2. Parenteral 14.24.3. Topical 14.25. Japan ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 14.25.1. Hospital Pharmacies 14.25.2. Online Pharmacies 14.25.3. Retail Pharmacies 14.25.4. Drug stores 14.26. South Korea ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 14.26.1. Barbiturates 14.26.2. Benzodiazepines 14.26.3. Hydantoins 14.26.4. Succinimides 14.27. South Korea ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 14.27.1. Epilepsy 14.27.2. Fibromyalgia 14.27.3. Migraine 14.27.4. Neuropathic pain 14.27.5. Bipolar disorder 14.27.6. Borderline personality disorder 14.28. South Korea ANTICONVULSANTS DRUGS Market Forecast, By Formulation 14.28.1. Enteral 14.28.2. Parenteral 14.28.3. Topical 14.29. South Korea ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 14.29.1. Hospital Pharmacies 14.29.2. Online Pharmacies 14.29.3. Retail Pharmacies 14.29.4. Drug stores 14.30. Australia ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 14.30.1. Barbiturates 14.30.2. Benzodiazepines 14.30.3. Hydantoins 14.30.4. Succinimides 14.31. Australia ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 14.31.1. Epilepsy 14.31.2. Fibromyalgia 14.31.3. Migraine 14.31.4. Neuropathic pain 14.31.5. Bipolar disorder 14.31.6. Borderline personality disorder 14.32. Australia ANTICONVULSANTS DRUGS Market Forecast, By Formulation 14.32.1. Enteral 14.32.2. Parenteral 14.32.3. Topical 14.33. Australia ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 14.33.1. Hospital Pharmacies 14.33.2. Online Pharmacies 14.33.3. Retail Pharmacies 14.33.4. Drug stores 14.34. ASEAN ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 14.34.1. Barbiturates 14.34.2. Benzodiazepines 14.34.3. Hydantoins 14.34.4. Succinimides 14.35. ASEAN ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 14.35.1. Epilepsy 14.35.2. Fibromyalgia 14.35.3. Migraine 14.35.4. Neuropathic pain 14.35.5. Bipolar disorder 14.35.6. Borderline personality disorder 14.36. ASEAN ANTICONVULSANTS DRUGS Market Forecast, By Formulation 14.36.1. Enteral 14.36.2. Parenteral 14.36.3. Topical 14.37. ASEAN ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 14.37.1. Hospital Pharmacies 14.37.2. Online Pharmacies 14.37.3. Retail Pharmacies 14.37.4. Drug stores 14.38. Rest of Asia Pacific ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 14.38.1. Barbiturates 14.38.2. Benzodiazepines 14.38.3. Hydantoins 14.38.4. Succinimides 14.39. Rest of Asia Pacific ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 14.39.1. Epilepsy 14.39.2. Fibromyalgia 14.39.3. Migraine 14.39.4. Neuropathic pain 14.39.5. Bipolar disorder 14.39.6. Borderline personality disorder 14.40. Rest of Asia Pacific ANTICONVULSANTS DRUGS Market Forecast, By Formulation 14.40.1. Enteral 14.40.2. Parenteral 14.40.3. Topical 14.41. Rest of Asia Pacific ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 14.41.1. Hospital Pharmacies 14.41.2. Online Pharmacies 14.41.3. Retail Pharmacies 14.41.4. Drug stores 14.42. Asia Pacific ANTICONVULSANTS DRUGS Market Attractiveness Analysis 14.42.1. By Therapeutic Class 14.42.2. By Disease Indication 14.42.3. By Formulation 14.42.4. By Distribution Channels 14.43. PEST Analysis 14.44. Key Trends 14.45. Key Developments 15. Middle East & Africa ANTICONVULSANTS DRUGS Market Analysis 15.1. Key Findings 15.2. Middle East & Africa ANTICONVULSANTS DRUGS Market Overview 15.3. Middle East & Africa ANTICONVULSANTS DRUGS Market Value Share Analysis, By Therapeutic Class 15.4. Middle East & Africa ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 15.4.1. Barbiturates 15.4.2. Benzodiazepines 15.4.3. Hydantoins 15.4.4. Succinimides 15.5. Middle East & Africa ANTICONVULSANTS DRUGS Market Value Share Analysis, By Disease Indication 15.6. Middle East & Africa ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 15.6.1. Epilepsy 15.6.2. Fibromyalgia 15.6.3. Migraine 15.6.4. Neuropathic pain 15.6.5. Bipolar disorder 15.6.6. Borderline personality disorder 15.7. Middle East & Africa ANTICONVULSANTS DRUGS Market Value Share Analysis, By Formulation 15.8. Middle East & Africa ANTICONVULSANTS DRUGS Market Forecast, By Formulation 15.8.1. Enteral 15.8.2. Parenteral 15.8.3. Topical 15.9. Middle East & Africa ANTICONVULSANTS DRUGS Market Value Share Analysis, By Distribution Channels 15.10. Middle East & Africa ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 15.10.1. Hospital Pharmacies 15.10.2. Online Pharmacies 15.10.3. Retail Pharmacies 15.10.4. Drug stores 15.11. Middle East & Africa ANTICONVULSANTS DRUGS Market Value Share Analysis, By Country 15.12. Middle East & Africa ANTICONVULSANTS DRUGS Market Forecast, By Country 15.12.1. GCC Countries 15.12.2. South Africa 15.12.3. Nigeria 15.12.4. Egypt 15.12.5. Rest of Middle East & Africa 15.13. Middle East & Africa ANTICONVULSANTS DRUGS Market Analysis, By Country 15.14. GCC Countries ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 15.14.1. Barbiturates 15.14.2. Benzodiazepines 15.14.3. Hydantoins 15.14.4. Succinimides 15.15. GCC Countries ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 15.15.1. Epilepsy 15.15.2. Fibromyalgia 15.15.3. Migraine 15.15.4. Neuropathic pain 15.15.5. Bipolar disorder 15.15.6. Borderline personality disorder 15.16. GCC Countries ANTICONVULSANTS DRUGS Market Forecast, By Formulation 15.16.1. Enteral 15.16.2. Parenteral 15.16.3. Topical 15.17. GCC Countries ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 15.17.1. Hospital Pharmacies 15.17.2. Online Pharmacies 15.17.3. Retail Pharmacies 15.17.4. Drug stores 15.18. South Africa ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 15.18.1. Barbiturates 15.18.2. Benzodiazepines 15.18.3. Hydantoins 15.18.4. Succinimides 15.19. South Africa ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 15.19.1. Epilepsy 15.19.2. Fibromyalgia 15.19.3. Migraine 15.19.4. Neuropathic pain 15.19.5. Bipolar disorder 15.19.6. Borderline personality disorder 15.20. South Africa ANTICONVULSANTS DRUGS Market Forecast, By Formulation 15.20.1. Enteral 15.20.2. Parenteral 15.20.3. Topical 15.21. South Africa ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 15.21.1. Hospital Pharmacies 15.21.2. Online Pharmacies 15.21.3. Retail Pharmacies 15.21.4. Drug stores 15.22. Nigeria ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 15.22.1. Barbiturates 15.22.2. Benzodiazepines 15.22.3. Hydantoins 15.22.4. Succinimides 15.23. Nigeria ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 15.23.1. Epilepsy 15.23.2. Fibromyalgia 15.23.3. Migraine 15.23.4. Neuropathic pain 15.23.5. Bipolar disorder 15.23.6. Borderline personality disorder 15.24. Nigeria ANTICONVULSANTS DRUGS Market Forecast, By Formulation 15.24.1. Enteral 15.24.2. Parenteral 15.24.3. Topical 15.25. Nigeria ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 15.25.1. Hospital Pharmacies 15.25.2. Online Pharmacies 15.25.3. Retail Pharmacies 15.25.4. Drug stores 15.26. Egypt ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 15.26.1. Barbiturates 15.26.2. Benzodiazepines 15.26.3. Hydantoins 15.26.4. Succinimides 15.27. Egypt ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 15.27.1. Epilepsy 15.27.2. Fibromyalgia 15.27.3. Migraine 15.27.4. Neuropathic pain 15.27.5. Bipolar disorder 15.27.6. Borderline personality disorder 15.28. Egypt ANTICONVULSANTS DRUGS Market Forecast, By Formulation 15.28.1. Enteral 15.28.2. Parenteral 15.28.3. Topical 15.29. Egypt ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 15.29.1. Hospital Pharmacies 15.29.2. Online Pharmacies 15.29.3. Retail Pharmacies 15.29.4. Drug stores 15.30. Rest of Middle East & Africa ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 15.30.1. Barbiturates 15.30.2. Benzodiazepines 15.30.3. Hydantoins 15.30.4. Succinimides 15.31. Rest of Middle East & Africa ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 15.31.1. Epilepsy 15.31.2. Fibromyalgia 15.31.3. Migraine 15.31.4. Neuropathic pain 15.31.5. Bipolar disorder 15.31.6. Borderline personality disorder 15.32. Rest of Middle East & Africa ANTICONVULSANTS DRUGS Market Forecast, By Formulation 15.32.1. Enteral 15.32.2. Parenteral 15.32.3. Topical 15.33. Rest of Middle East & Africa ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 15.33.1. Hospital Pharmacies 15.33.2. Online Pharmacies 15.33.3. Retail Pharmacies 15.33.4. Drug stores 15.34. Middle East & Africa ANTICONVULSANTS DRUGS Market Attractiveness Analysis 15.34.1. By Therapeutic Class 15.34.2. By Disease Indication 15.34.3. By Formulation 15.34.4. By Distribution Channels 15.35. PEST Analysis 15.36. Key Trends 15.37. Key Developments 16. South America ANTICONVULSANTS DRUGS Market Analysis 16.1. Key Findings 16.2. South America ANTICONVULSANTS DRUGS Market Overview 16.3. South America ANTICONVULSANTS DRUGS Market Value Share Analysis, By Therapeutic Class 16.4. South America ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 16.4.1. Barbiturates 16.4.2. Benzodiazepines 16.4.3. Hydantoins 16.4.4. Succinimides 16.5. South America ANTICONVULSANTS DRUGS Market Value Share Analysis, By Disease Indication 16.6. South America ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 16.6.1. Epilepsy 16.6.2. Fibromyalgia 16.6.3. Migraine 16.6.4. Neuropathic pain 16.6.5. Bipolar disorder 16.6.6. Borderline personality disorder 16.7. South America ANTICONVULSANTS DRUGS Market Value Share Analysis, By Formulation 16.8. South America ANTICONVULSANTS DRUGS Market Forecast, By Formulation 16.8.1. Enteral 16.8.2. Parenteral 16.8.3. Topical 16.9. South America ANTICONVULSANTS DRUGS Market Value Share Analysis, By Distribution Channels 16.10. South America ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 16.10.1. Hospital Pharmacies 16.10.2. Online Pharmacies 16.10.3. Retail Pharmacies 16.10.4. Drug stores 16.11. South America ANTICONVULSANTS DRUGS Market Value Share Analysis, By Country 16.12. South America ANTICONVULSANTS DRUGS Market Forecast, By Country 16.12.1. Brazil 16.12.2. Colombia 16.12.3. Argentina 16.12.4. Rest of South America 16.13. South America ANTICONVULSANTS DRUGS Market Analysis, By Country 16.14. Brazil ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 16.14.1. Barbiturates 16.14.2. Benzodiazepines 16.14.3. Hydantoins 16.14.4. Succinimides 16.15. Brazil ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 16.15.1. Epilepsy 16.15.2. Fibromyalgia 16.15.3. Migraine 16.15.4. Neuropathic pain 16.15.5. Bipolar disorder 16.15.6. Borderline personality disorder 16.16. Brazil ANTICONVULSANTS DRUGS Market Forecast, By Formulation 16.16.1. Enteral 16.16.2. Parenteral 16.16.3. Topical 16.17. Brazil ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 16.17.1. Hospital Pharmacies 16.17.2. Online Pharmacies 16.17.3. Retail Pharmacies 16.17.4. Drug stores 16.18. Colombia ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 16.18.1. Barbiturates 16.18.2. Benzodiazepines 16.18.3. Hydantoins 16.18.4. Succinimides 16.19. Colombia ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 16.19.1. Epilepsy 16.19.2. Fibromyalgia 16.19.3. Migraine 16.19.4. Neuropathic pain 16.19.5. Bipolar disorder 16.19.6. Borderline personality disorder 16.20. Colombia ANTICONVULSANTS DRUGS Market Forecast, By Formulation 16.20.1. Enteral 16.20.2. Parenteral 16.20.3. Topical 16.21. Colombia ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 16.21.1. Hospital Pharmacies 16.21.2. Online Pharmacies 16.21.3. Retail Pharmacies 16.21.4. Drug stores 16.22. Argentina ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 16.22.1. Barbiturates 16.22.2. Benzodiazepines 16.22.3. Hydantoins 16.22.4. Succinimides 16.23. Argentina ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 16.23.1. Epilepsy 16.23.2. Fibromyalgia 16.23.3. Migraine 16.23.4. Neuropathic pain 16.23.5. Bipolar disorder 16.23.6. Borderline personality disorder 16.24. Argentina ANTICONVULSANTS DRUGS Market Forecast, By Formulation 16.24.1. Enteral 16.24.2. Parenteral 16.24.3. Topical 16.25. Argentina ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 16.25.1. Hospital Pharmacies 16.25.2. Online Pharmacies 16.25.3. Retail Pharmacies 16.25.4. Drug stores 16.26. Rest of South America ANTICONVULSANTS DRUGS Market Forecast, By Therapeutic Class 16.26.1. Barbiturates 16.26.2. Benzodiazepines 16.26.3. Hydantoins 16.26.4. Succinimides 16.27. Rest of South America ANTICONVULSANTS DRUGS Market Forecast, By Disease Indication 16.27.1. Epilepsy 16.27.2. Fibromyalgia 16.27.3. Migraine 16.27.4. Neuropathic pain 16.27.5. Bipolar disorder 16.27.6. Borderline personality disorder 16.28. Rest of South America ANTICONVULSANTS DRUGS Market Forecast, By Formulation 16.28.1. Enteral 16.28.2. Parenteral 16.28.3. Topical 16.29. Rest of South America ANTICONVULSANTS DRUGS Market Forecast, By Distribution Channels 16.29.1. Hospital Pharmacies 16.29.2. Online Pharmacies 16.29.3. Retail Pharmacies 16.29.4. Drug stores 16.30. South America ANTICONVULSANTS DRUGS Market Attractiveness Analysis 16.30.1. By Therapeutic Class 16.30.2. By Disease Indication 16.30.3. By Formulation 16.30.4. By Distribution Channels 16.31. PEST Analysis 16.32. Key Trends 16.33. Key Developments 17. Company Profiles 17.1. Market Share Analysis, By Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players By price, presence, market share, Component, and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A By Regions, Investment and Component 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.3. Company Profiles: Key Players 17.3.1. Abbott Laboratories 17.3.1.1. Company Overview 17.3.1.2. Financial Overview 17.3.1.3. Product Portfolio 17.3.1.4. Business Strategy 17.3.1.5. Recent Developments 17.3.1.6. Development Footprint 17.3.2. Teva Pharmaceuticals 17.3.3. Johnson & Johnson 17.3.4. Novartis 17.3.5. Pfizer 17.3.6. Valeant pharmaceuticals 17.3.7. Sanofi 17.3.8. UCB 17.3.9. Shire 17.3.10. AstraZeneca 17.3.11. GlaxoSmithKline 17.3.12. Sunovion Pharmaceuticals 17.3.13. GW Pharmaceuticals 17.3.14. H. Lundbeck 17.3.15. Cephalon Inc. 17.3.16. Sumitomo Dainippon Pharma 18. Primary key Insights
